SubsidieMeestersHuman-Centric AI platform for heALth and Life sciences
Abzu ApS aims to revolutionize AI in pharma with the QLattice, a user-friendly, explainable platform that enhances R&D efficiency and reduces costs, supported by EIC funding.
Projectdetails
Introduction
Abzu ApS – an EU-based deep-tech start-up – is redefining the AI landscape with an explainable, accurate, and scalable solution – the QLattice – poised to disrupt the global AI race as the first truly responsible, trustworthy, and transparent AI.
EIC Support and Development
With EIC support and based on 15+ pharma pilots with second to none explainable and accurate insights, Abzu will develop Reason – a tailor-made platform for pharma readily utilized by non-code savvy R&D scientists.
Current Challenges
Current black box solutions lack user-friendliness and have failed to restrain steady R&D cost increases in the last 15 years (~€2.5B per drug today).
Proposed Solution
Reason will reverse this trend with added value in key metrics of increased ROI, productivity, and treatment availability.
Strategic Goals
Abzu’s business, technology, and the EU’s strategic goals are at a unique crossroads of technological, societal, and economic disruption.
Future Outlook
EIC funds will make Abzu the next EU unicorn and result in the EU disrupting and gaining a foothold in the global AI market.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.495.099 |
| Totale projectbegroting | € 3.564.427 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ABZU APSpenvoerder
- ABZU BARCELONA S.L.
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancerQlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe. | EIC Accelerator | € 2.491.650 | 2024 | Details |
The first utility-oriented, agnostic software platform for quantum-centric drug discoveryKvantify is developing Kvaser, a user-friendly quantum software tool for R&D scientists to perform advanced molecular simulations, enhancing drug discovery with speed and precision. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Multi-omic data driven drug discovery and indication prioritisation platform in oncologymCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies. | EIC Accelerator | € 2.495.788 | 2022 | Details |
A Digital R&D team member, automating scientific knowledge handling, allowing European R&D to increase their speed of innovationThe project aims to enhance corporate innovation in the EU by developing a Digital R&D team member using advanced Machine Learning to reduce researchers' data handling time by 30%. | EIC Accelerator | € 2.387.000 | 2023 | Details |
Next generation HPC/QC in silico drug discovery platform for de novo designATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer
Qlucore aims to revolutionize precision oncology by developing AI-driven diagnostic software for cancer, enhancing accuracy in gene analysis and improving survival rates across Europe.
The first utility-oriented, agnostic software platform for quantum-centric drug discovery
Kvantify is developing Kvaser, a user-friendly quantum software tool for R&D scientists to perform advanced molecular simulations, enhancing drug discovery with speed and precision.
Multi-omic data driven drug discovery and indication prioritisation platform in oncology
mCUBE is an AI-driven platform aimed at enhancing precision oncology by harmonizing clinical data and multi-omic analysis to identify new drug candidates for licensing to pharma companies.
A Digital R&D team member, automating scientific knowledge handling, allowing European R&D to increase their speed of innovation
The project aims to enhance corporate innovation in the EU by developing a Digital R&D team member using advanced Machine Learning to reduce researchers' data handling time by 30%.
Next generation HPC/QC in silico drug discovery platform for de novo design
ATLAS is an advanced in silico drug discovery platform that aims to reduce costs and cycle times by 50%, with plans to generate new drug candidates every 18 months and expand into the US market by 2027.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
eXplainable AI in Personalized Mental HealthcareDit project ontwikkelt een innovatief AI-platform dat gebruikers betrekt bij het verbeteren van algoritmen via feedbackloops, gericht op transparantie en betrouwbaarheid in de geestelijke gezondheidszorg. | Mkb-innovati... | € 350.000 | 2022 | Details |
Accelerated Discovery Nanobody PlatformThe ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing. | EIC Pathfinder | € 3.315.441 | 2024 | Details |
Versnelling;AI voor en door de ZorgHet project ontwikkelt generieke AI-toepassingen in samenwerking met ziekenhuizen om zorgverleners te ondersteunen met voorspellingsinformatie, gericht op opschaling en verbetering van de zorg. | Mkb-innovati... | € 187.150 | 2022 | Details |
Drug Discovery IntelligenceHet project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties. | Mkb-innovati... | € 20.000 | 2020 | Details |
Ontwikkeling AI AquacultureHet project ontwikkelt een AI-platform voor geautomatiseerde monitoring en analyse van kweekvis, ter verbetering van dierenwelzijn en voedselkwaliteit. | Mkb-innovati... | € 171.045 | 2023 | Details |
eXplainable AI in Personalized Mental Healthcare
Dit project ontwikkelt een innovatief AI-platform dat gebruikers betrekt bij het verbeteren van algoritmen via feedbackloops, gericht op transparantie en betrouwbaarheid in de geestelijke gezondheidszorg.
Accelerated Discovery Nanobody Platform
The ALADDIN project aims to revolutionize therapeutic antibody discovery for cancer by integrating nanobody technology, AI tools, and innovative models to enhance efficiency and reduce reliance on animal testing.
Versnelling;AI voor en door de Zorg
Het project ontwikkelt generieke AI-toepassingen in samenwerking met ziekenhuizen om zorgverleners te ondersteunen met voorspellingsinformatie, gericht op opschaling en verbetering van de zorg.
Drug Discovery Intelligence
Het project ontwikkelt een AI-gestuurde softwareapplicatie om risico's in de medicijnontwikkeling te verminderen door het voorspellen van therapeutische targets en drug-target interacties.
Ontwikkeling AI Aquaculture
Het project ontwikkelt een AI-platform voor geautomatiseerde monitoring en analyse van kweekvis, ter verbetering van dierenwelzijn en voedselkwaliteit.